Peter Lynch fit · Growth at a reasonable price (GARP)
Is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
7/100
FPas un fit
2/6 critères validés
Les critères de Peter Lynch, appliqués à KNSA
PEG ≤ 1.0
clé—
EPS CAGR ≥ 15%
clé0.0%
Revenue CAGR ≥ 10%
6.6%
Net margin > 0
—
Comment KNSA se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$4B
PER (TTM)
61.4x
ROIC (TTM)
9.56%
Marge brute
54.63%
Autres analyses Peter Lynch
Questions fréquentes
What is KNSA's Peter Lynch fit score?
KNSA scores 7/100 on our Peter Lynch fit engine — grade F. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own KNSA?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends KNSA.
How often is this score updated?
KNSA's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande KNSA personnellement.